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Abstract
Background: Visual assessment rating scales for medial temporal lobe (MTL) atrophy have been used by neuroradiologists
in clinical practice to aid the diagnosis of Alzheimer’s disease (AD). Recently multivariate classification methods for magnetic
resonance imaging (MRI) data have been suggested as alternative tools. If computerized methods are to be implemented in
clinical practice they need to be as good as, or better than experienced neuroradiologists and carefully validated. The aims
of this study were: (1) To compare the ability of MTL atrophy visual assessment rating scales, a multivariate MRI classification
method and manually measured hippocampal volumes to distinguish between subjects with AD and healthy elderly
controls (CTL). (2) To assess how well the three techniques perform when predicting future conversion from mild cognitive
impairment (MCI) to AD.
Methods: High resolution sagittal 3D T1w MP-RAGE datasets were acquired from 75 AD patients, 101 subjects with MCI and
81 CTL from the multi-centre AddNeuroMed study. An automated analysis method was used to generate regional volume
and regional cortical thickness measures, providing 57 variables for multivariate analysis (orthogonal partial least squares to
latent structures using seven-fold cross-validation). Manual hippocampal measurements were also determined for each
subject. Visual rating assessment of MTL atrophy was performed by an experienced neuroradiologist according to the
approach of Scheltens et al.
Results: We found prediction accuracies for distinguishing between AD and CTL of 83% for multivariate classification, 81%
for the visual rating assessments and 89% for manual measurements of total hippocampal volume. The three different
techniques showed similar accuracy in predicting conversion from MCI to AD at one year follow-up.
Conclusion: Visual rating assessment of the MTL gave similar prediction accuracy to multivariate classification and manual
hippocampal volumes. This suggests a potential future role for computerized methods as a complement to clinical
assessment of AD.
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Introduction
Dementia is the third most common cause of death in society
today, exceeded only by cancer and cardiovascular disorders and
Alzheimer’s disease (AD) is the most common form of dementia.
Biomarkers of AD based on non-invasive in vivo methods are highly
desirable for diagnosis, monitoring disease progression and
evaluating disease-modifying treatment strategies. An ideal
biomarker would detect a fundamental feature of AD neuropa-
thology, be diagnostically sensitive and specific, and produce
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Imaging (MRI), Positron Emission Tomography (PET), and
cerebrospinal fluid (CSF) measures all allow different aspects of
AD pathology to be studied. The new suggested research criterion
for AD is centered on a clinical core of early and significant
episodic memory impairment and at least one abnormal
biomarker from MRI, PET and CSF [2] and the new suggested
diagnostic criterion also utilize biomarkers [3].
Several groups including our own have proposed the use of
multivariate techniques for analyzing multiple regional measures
from MRI to aid diagnosis of AD and to predict future conversion
from the prodromal stages of the disease often referred to as mild
cognitive impairment (MCI) to AD. Previous studies have shown
that computerized methods give high prediction accuracies when
distinguishing between patient groups [4,5,6,7]. If computerized
methods based on MRI are to be useful in clinical practice then
they will need to be as good as or better than experienced
neuroradiologists. Klo ¨ppel et al. previously compared the
diagnostic accuracy of a computerized method (support vector
machines (SVM)) with radiological expertise, concluding that
SVM gives comparable results to a well-trained neuroradiologist
[8]. The study had the strength of using neuropathologically
confirmed images, however they did not use a validated and
widely used clinical rating scale and they studied relatively small
cohorts.
We recently used the multivariate method orthogonal partial
least squares to latent structures (OPLS) with multiple regional
volumes and cortical thickness measures as input to investigate
patterns of atrophy and prediction accuracy in two large
multicenter cohorts (AddNeuroMed and the Alzheimer’s Disease
Neuroimaging Initiative (ADNI)). The study included over a
thousand patients and we found prediction accuracies between
83–87% when discriminating between AD and controls [9].
The aim of the current study is to compare the performance of
the OPLS multivariate technique with that of an experienced
neuroradiologist using data from the AddNeuroMed cohort (a part
of InnoMed, (Innovative Medicines in Europe), an Integrated
Project funded by the European Union Sixth Framework
programme) [10,11]. The method used for visual rating assessment
is the well established Scheltens method which uses a five point
scale to grade atrophy in the medial temporal lobe [12]. To our
knowledge this is the first comparison of the Scheltens visual rating
scale for assessment of AD with a computerized method.
Additionally our study uses a substantially larger cohort than the
earlier study by Klo ¨ppel et al, and we also include subjects with
mild cognitive impairment. For further evaluation we also aimed
to compare the visual rating assessment with manual hippocampal
measures. Manual measures have been used for AD diagnosis in
research for many years and this region is one part of the visual
rating assessment protocol described by Scheltens et al. However,
manual hippocampal measurements are time consuming and not
feasible in clinical practice. The different approaches were
compared in two steps, firstly by distinguishing between AD and
controls, and secondly by assessing how well the approaches
predicted conversion of MCI subjects at baseline to AD at one
year follow-up.
Materials and Methods
Ethics Statement
Written consent was obtained where the research participant
had capacity, and in those cases where dementia compromised
capacity then assent from the patient and written consent from a
relative, according to local law and process, was obtained. This
study was approved by ethical review boards in each participating
country (local ethical review board at University of Perugia,
University of Toulouse, Aristotle University of Thessaloniki,
Medical University of Lodz, University of Eastern Finland and
University Hospital of Kuopio and King’s College London).
Study data and inclusion and diagnostic criteria
All patients originated from the AddNeuroMed project, part of
InnoMed (Innovative Medicines in Europe), a European Union
program designed to make drug discovery more efficient. The
project is designed to develop and validate novel surrogate
markers in Alzheimer’s disease (AD) and includes a human
neuroimaging strand [13,14] which combines MRI data with
other biomarkers and clinical data. Data was collected from six
different sites across Europe; University of Kuopio, Finland,
University of Perugia, Italy, Aristotle University of Thessaloniki,
Greece, King’s College London, United Kingdom, University of
Lodz, Poland and University of Toulouse, France. MRI images
from a total of 252 subjects were included in this study; 75 AD
patients, 101 MCI patients and 81 healthy controls. Demographics
of the cohort are given in Table 1. All AD and MCI subjects were
recruited from local memory clinics of the six participating sites
while the control subjects were recruited from non-related
members of the patient’s families, caregiver’s relatives or social
centres for the elderly. The inclusion and exclusion criteria were as
follows.
Alzheimer’s disease. Inclusion criteria: 1) ADRDA/NINCDS
and DSM- IV criteria for probable Alzheimer’s disease. 2) Mini
Mental State Examination score range between 12 and 28. 4) Age
65 years or above. Exclusion criteria: 1) Significant neurological or
psychiatric illness other than Alzheimer’s disease. This would
exclude patients with vascular dementia or large infarcts. 2)
Significant unstable systematic illness or organ failure. All AD
subjects had a Clinical Dementia Rating (CDR) scale score of 0.5
or above.
Mild Cognitive Impairment and Controls. Inclusion criteria:
1) Mini Mental State Examination score range between 24 and 30.
2) Geriatric Depression Scale score less than or equal to 5. 3) Age
65 years or above. 4) Medication stable. 5) Good general health.
Exclusion criteria: 1) Meet the DSM- IV criteria for Dementia. 2)
Significant neurological or psychiatric illness other than
Alzheimer’s disease. 3) Significant unstable systematic illness or
organ failure. The distinction between MCI and controls was
based on two criteria: 1) subject scores 0 on Clinical Dementia
Table 1. Subject characteristics.
AddNeuroMed
CTL MCI AD
Number 81 101 75
Female/Male 45/36 52/49 50/25
Age 73.666.3 74.065.8 74.266.0
Education 11.064.8 8.764.3 8.364.2
MMSE 29.061.2 27.261.6 21.364.6
CDR 0 0.5 1.160.5
ADAS1 3.461.5 5.361.2 6.661.5
Data are represented as mean 6 standard deviation. AD=Alzheimer’s disease,
MCI=Mild Cognitive Impairment, CTL=healthy control, Education in years,
MMSE=Mini Mental State Examination, ADAS1=Word list non-learning (mean),
CDR=Clinical Dementia Rating.
doi:10.1371/journal.pone.0022506.t001
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Rating scale=MCI. For the MCI subjects it was preferable that
the subject and informant reported occurrence of memory
problems.
CDR, Mini-Mental State, and CERAD Cognitive Battery were
assessed for each subject. The CERAD Cognitive Battery was
replaced with the Alzheimer’s Disease Assessment Scale (ADAS–
Cog) for the AD subjects. This cognitive test battery is specially
designed for AD trials [15]. Both the ADAS-cog and the CERAD
battery use the same 10-word recall task. The only difference is
that the scoring is inverted. The mean number of words not
recalled in the CERAD word list immediate recall task was
calculated. The variable obtained was named ADAS1, corre-
sponding to the first subtest of ADAS-Cog. This was performed to
obtain comparable measures between groups.
MRI
Data acquisition for the AddNeuroMed study was designed to be
compatible with the Alzheimer Disease Neuroimaging Initiative
(ADNI) [16]. The imaging protocol for both studies included a high
resolution sagittal 3D T1-weighted MPRAGE volume (voxel size
1.161.161.2 mm
3) and axial proton density/T2-weighted fast spin
echo images. The MPRAGE volume was acquired using a custom
pulse sequence specifically designed for the ADNI study to ensure
compatibilityacrossscanners[16].Fullbrainand skullcoverage was
required for both of the latter datasets and detailed quality control
carried out on all MR images from both studies according to the
AddNeuroMed quality control procedure [13,14].
Regional volume segmentation and cortical thickness
parcellation
We utilized a pipeline, developed by Fischl and Dale which
produces regional cortical thickness and volumetric measures
(Figure 1). Cortical reconstruction and volumetric segmentation
includes removal of non-brain tissue using a hybrid watershed/
surface deformation procedure [17], automated Talairach trans-
formation, segmentation of the subcortical white matter and deep
grey matter volumetric structures (including hippocampus, amyg-
dala, caudate, putamen, ventricles) [17,18,19] intensity normaliza-
tion [20], tessellation of the grey matter white matter boundary,
automated topology correction [21,22], and surface deformation
following intensity gradients to optimally place the grey/white and
grey/cerebrospinal fluid borders at the location where the greatest
shift in intensity defines the transition to the other tissue class
[23,24,25]. Once the cortical models are complete, registration to a
spherical atlas takes place which utilizes individual cortical folding
patterns to match cortical geometry across subjects [26]. This is
followed by parcellation of the cerebral cortex into units based on
gyral and sulcal structure [27,28]. Left and right sided volumes and
thicknesses were averaged. The regional cortical thickness was
measured from 34 areas and the regional volumes were measured
from 23 areas. All volumetric measures from each subject were
normalized by the subject’s intracranial volume. This segmentation
approach has been used for multivariate classification of Alzhei-
mer’s disease and healthy controls [7], neuropsychological-image
analysis [29,30,31], imaging-genetic analysis [32,33] and biomarker
discovery [34].
Figure 1. Representations of ROIs included as candidate input variables in the multivariate OPLS model. (A) Regional volumes. (B)
Regional cortical thickness measures.
doi:10.1371/journal.pone.0022506.g001
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atrophy
The 3D T1-weighted MPRAGE images were reoriented to an
oblique coronal orientation perpendicular to the AC-PC (anterior
commisure - posterior commisure) line suitable for both volumetric
and visual assessment. Visual assessment of the medial temporal
lobe atrophy was performed on a single MR-slice posterior to the
amygdala and the mamillary bodies positioned such that the
hippocampus, the pons and the cerebral peduncles are all covered
by the slice. The rating scheme used here was first proposed by
Scheltens et al. [12] and is based on a visual estimation of volume
of the medial temporal lobe. The visual assessment includes
hippocampus proper, dentate gyrus, subiculum, parahippocampal
gyrus, entorhinal cortex and surrounding CSF spaces such as the
temporal horns and choroid fissure. The right and left sides are
rated separately. Scores range from 0 (no atrophy) to 4 (end stage
atrophy) as detailed in Table 2 and Figure 2. For subjects ,75
years, a MTA score of 2 or more is considered abnormal, while for
subjects .75 years, a MTA score of 3 or more is considered
abnormal (http://www.radiologyassistant.nl/en/43dbf6d16f98d).
The rater (LC) was blinded to diagnosis, gender and age. Intra-
rater reliability of the visual assessment of the medial temporal
lobe atrophy was tested in 100 randomly selected subjects by
repeated assessment with an interval of one week. Intra-rater
reliability was 0.81 on right side and on left side 0.78. Weighted
kappa was 0.93 on both sides.
Manual segmentation of hippocampus
Manual measurements of hippocampal volume were performed
on a HERMES workstation (Nuclear Diagnostics, Stockholm,
Sweden). Each measurement was performed with constant
parameters by a neuroradiologist (YZ) who was blinded to clinical
information. A ROI tool was used within the HERMES Multi-
modality software package, to manually delineate the hippocampal
formation using previously defined anatomical landmarks [35].
Intra-rater reliability of the measurements was tested in 15
randomly selected subjects by repeated measurements with an
interval of one month. The intra class correlation coefficients
(ICC) of the measurements were .0.93. The total hippocampal
volume from each subject was normalized by the subjects’
intracranial volume.
Multivariate data analysis
MRI measures were analyzed using orthogonal partial least
squares to latent structures (OPLS) [6,7,36,37,38,39], a supervised
multivariate data analysis method included in the software
package SIMCA (Umetrics AB, Umea, Sweden). A very similar
method, partial least square to latent structures (PLS) has
previously been used in several studies to analyze MR-data
[40,41,42,43,44]. OPLS and PLS give the same predictive
accuracy, but the advantage of OPLS is that the model created
to compare groups is rotated, which means that the information
related to class separation is found in the first component of the
model, the predictive component. The other orthogonal compo-
nents in the model, if any, relate to variation in the data not
connected to class separation. Focusing the information related to
class separation on the first component makes data interpretation
easier [39].
Pre-processing was performed using mean centring and unit
variance scaling. Mean centring improves the interpretability of
the data, by subtracting the variable average from the data. By
doing so the data set is repositioned around the origin. Large
variance variables are more likely to be expressed in modeling
than low variance variables. Consequently, unit variance scaling
was selected to scale the data appropriately. This scaling method
calculates the standard deviation of each variable. The inverse
standard deviation is used as a scaling weight for each MR-
measure.
Table 2. Visual rating of the medial temporal lobe.
Scale
Width of
Choroid fissure
Width of
temporal horn
Hippocampal
thickness
0 NNN
1 q NN
2 qq q Q
3 qqq qq QQ
4 qqq qqq QQQ
Scheltens et al., 1992.
doi:10.1371/journal.pone.0022506.t002
Figure 2. Visual assessment of the medial temporal lobe
atrophy was performed on a single MR-slice posterior to the
amygdala and the mamillary bodies. The was positioned so the
hippocampus, the pons and the cerebral peduncles were all visible. The
visual assessment included hippocampus proper, dentate gyrus,
subiculum, parahippocampal gyrus, entorhinal cortex and surrounding
CSF spaces such as temporal horn and choroid fissure. The right and left
side were rated separately. Scores range from 0 (no atrophy) to 4 (end
stage atrophy).
doi:10.1371/journal.pone.0022506.g002
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plot by plotting the predictive component, which contains the
information related to class separation. Components are vectors,
which are linear combinations of partial vectors and are
dominated by the input variables (x). The first and second
components are by definition orthogonal to each other and span
the projection plane of the points. Each point in the scatter plot
represents one individual subject. The predictive component
receives a Q
2(Y) value that describes its statistical significance for
separating groups. Q
2(Y) values .0.05 are regarded as statistically
significant [45], where
Q
2 Y ðÞ ~1{PRESS=SSY ð1Þ
where PRESS (predictive residual sum of squares)=S(yactual2
ypredicted)
2 and SSY is the total variation of the Y matrix after
scaling and mean centring [45]. Q
2(Y) is the fraction of the total
variation of the Ys (expected class values) that can be predicted by
a component according to cross validation (CV). Cross validation
is a statistical method for validating a predictive model which
involves building a number of parallel models. These models differ
from each other by leaving out a part of the data set each time.
The data omitted is then predicted by the respective model. In this
study we used seven fold cross-validation, which means that 1/7th
of the data is omitted for each cross-validation round. Data is
omitted once and only once. Variables were plotted according to
their importance for the separation of groups. The plot shows the
MRI measures and their corresponding jack-knifed confidence
intervals. Jack-knifing is used to estimate the bias and standard
error. Measures with confidence intervals that include zero have
low reliability [39]. Covariance is plotted on the y-axis, where
Cov t,Xi ðÞ ~tTXi= N{1 ðÞ ð 2Þ
where t is the transpose of the score vector t in the OPLS model, i
is the centered variable in the data matrix X and N is the number
of variables [39]. A measure with high covariance is more likely to
have an impact on group separation than a variable with low
covariance. MRI measures below zero in the scatter plot have
lower values in controls compared to AD subjects, while MRI
measures above zero are higher in controls compared to AD
subjects in the model.
Altogether 57 variables were used for OPLS analysis. No feature
selection was performed, meaning all measured variables were
included in the analysis. A model containing age was also created
to test if there were any significant differences between the
diagnostic groups in relation to the variable. We investigated
whether age would increase the predictive power of the models
using it as an x-variable.
Sensitivity and specificity were calculated from the cross-
validated prediction values of the OPLS models and for the visual
assessment. Finally, the positive and negative likelihood ratios
(LR+=sensitivity/(1002specificity) and LR2=(1002sensitivity)/
specificity) were calculated. A positive likelihood ratio between 5–
10 or a negative likelihood ratio between 0.1–0.2 increases the
diagnostic value in a moderate way, while a value above 10 or
below 0.1 significantly increases the diagnostic value of the test
[46].
Finally the AD vs. CTL models were used as training sets to
investigate how well they could predict conversion from MCI to
AD after one year follow-up and how they compare to the visual
assessment. To easily compare the performance of the three
methods we also calculated the sensitivity (MCI-c predicted as AD)
at a fixed specificity (MCI-s predicted as CTL). We set the
specificity for all three methods for this comparison to that of the
visual assessment since this can not be changed and recalculated
the sensitivity and specificity for the other two methods.
Results
Subject cohort
252 subjects were included in this study: 75 AD patients, 101
MCI patients and 81 control subjects. Using age as an x-variable
in the OPLS models did not have any effect on the predictive
power of the models separating the groups when all image
variables were included. Therefore, age was excluded from further
analysis. All MRI volumetric measures were normalised by
dividing by each subject’s intracranial volume. As expected,
performance on the MMSE, CDR and ADAS1 was poorest
among AD patients and best among controls (Table 1). The MCI
group had scores between the AD and the control groups (Table 1).
OPLS modelling and quality
Two models were created using (1) total hippocampal volume
(2) automated regional volume and cortical thickness measures to
compare AD vs. controls. The first model using the total manual
hippocampal volume accounted for 100% of the variance of the
original data (R
2(X)) and its’ cross validated predictability,
Q
2(Y)=0.61. The second model using regional MRI measures
resulted in one predictive component with R
2(X)=60% and cross
validated predictability Q
2(Y)=0.45.
Classification accuracy of the different techniques
The separation between patients with AD and controls and the
predictive power of the models Q
2(Y) can be seen in Figure 3A
using automated regional volume and cortical thickness measures
as input. As can be observed there is a distinct separation between
AD and controls. This model resulted in a prediction accuracy of
82.7% (accuracy, sensitivity, specificity, positive likelihood ratio
and negative likelihood ratio given in Table 3). Figure 3B
illustrates the variables of importance for the distinction between
the two groups. The pattern of atrophy, including hippocampus,
amygdala and entorhinal cortex among other temporal lobe
regions, together with volume measures of CSF is as expected very
similar to previous analyses of the AddNeuroMed cohort using
regional MRI measures and an OPLS model [9]. Visual rating
assessment using the Scheltens scale resulted in a prediction
accuracy of 80.8%. Finally, total hippocampal volume yielded a
prediction accuracy of 89.1%. The best predictive result was
obtained from manual hippocampal measures closely followed by
the automated image pipeline with OPLS and lastly the visual
rating assessment.
Predicting conversion from MCI at baseline to AD at one
year follow-up
Finally, we wanted to investigate how the three different
approaches would predict conversion from MCI at baseline to AD
at one year clinical follow-up. All MCI subjects were classified as
either AD or control like using OPLS models (AD vs. CTL). The
visual assessment for the MCI subjects were performed in the same
way, using the same cut offs as described previously, resulting in an
assessment of abnormal or normal brain changes with respect to
age. The results are shown in Table 4 demonstrating that 68% of
the MCI converters (MCI-c) were classified as more AD-like and
68% of the MCI stable (MCI-s) classified as more control-like at
baseline using visual rating assessment. Using automated regional
MRI measures as input to the OPLS model, 74% of the MCI-c
MTL Visual Ratings and Multivariate Classification
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predicted as more AD-like and 70% of the MCI-s were predicted
as more control-like at baseline. For the total hippocampal
volume, 79% of the MCI-c subjects who converted to AD at one
year follow-up were predicted as more AD-like and 54% of the
MCI-s were predicted as more control-like. When we set the
specificity (MCI-s predicted as CTL) to a fixed value (the
specificity of the visual assessment) to make the comparison of
the methods easier, the results were slightly altered (Table 4). The
best results were obtained from the OPLS model with automated
regional MRI measures as input, with 79% of MCI-c subjects who
converted to AD at one year follow-up predicted as more AD-like,
compared to 68% for the manual hippocampal volumes and
Scheltens visual assessment rating.
Discussion
Automated computerized MRI methods to aid in the diagnosis
of AD will only be implemented in clinical practice if they are
carefully investigated and validated. The aim of this study was to
further validate the OPLS technique with fully automated MRI
measures as input and compare it to the Scheltens scale for visual
assessment of medial temporal lobe atrophy and to that of total
hippocampal volume. To our knowledge this is the first time that
Figure 3. OPLS cross validated score plots and MRI measures of importance for the separation between AD and CTL. (A) The scatter
plot visualises group separation and the predictability of the AD vs. CTL model. Each black square represents an AD subject and each gray circle a
control subject. Control subjects to the left of zero and AD subjects to the right of zero are falsely predicted. Q
2(Y).0.05 (statistically significant
model). (B) Measures above zero have a larger value in controls compared to AD and measures below zero have a lower value in controls compared
to AD. A measure with a high covariance is more likely to have an impact on group separation than a measure with a low covariance. Measures with
jack knifed confidence intervals that include zero have low reliability.
doi:10.1371/journal.pone.0022506.g003
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computerized method. We wanted to investigate which approach
would distinguish between AD patients and controls with the
highest accuracy and best predict conversion from MCI to AD.
We have previously shown that combining a set of automated
measures of the brain together with manual measures of
hippocampus significantly improves the prediction accuracy using
OPLS [6]. Manual measures of different brain regions are time
consuming and operator dependent however and are hence not
regularly used in a clinical settings. Therefore we further
investigated the power of OPLS using only automated measures
as input (using the same volumes and cortical thickness measures
as used here) in two large cohorts (AddNeuroMed and Alzheimer’s
disease Neuroimaging Initiative (ADNI)). This was performed to
investigate if similar patterns of atrophy and prediction accuracy
could be obtained from two different large cohorts using the OPLS
model [9] and we found good comparability between the two
cohorts. We have also previously investigated the value of
combining magnetic resonance spectroscopy (MRS) with auto-
mated regional MRI measures using OPLS [7] which showed a
significant improvement compared with using either set of
measures individually. The next natural step was to compare the
OPLS technique with a well established visual rating assessment
scale such as the Scheltens scale, performed by an experienced
neuroradiologist, as we describe here.
Classification accuracy of the different techniques
The results suggest that the OPLS technique with fully
automated regional MRI measures as input performs better than
the visual rating assessments made by an experienced neuroradi-
ologist. The sensitivity of the two methods is similar resulting in
identical negative likelihood ratios (77.3%, 0.26 and 78.7%, 0.26
respectively), while the specificity was higher for the OPLS
technique than the visual assessment (87.7% and 82.7%) yielding a
higher positive likelihood ratio (6.3 and 4.6). The overall accuracy
was higher for the OPLS technique compared to the visual rating
scale (82.7% and 80.8%). When the specificity was fixed for all
three methods at the value of the visual rating assessments, the
sensitivity of the OPLS analysis (79%) was better than the other
two methods (both 68%). Although the manually measured total
hippocampal volume still yielded the best prediction accuracy, the
time consuming nature of manual measures makes them
impractical in a clinical settings. Manual measurements can also
be operator dependent and it can be hard to compare such
measures across sites and within sites if different operators are
used. If only positive likelihood ratios are considered then the
OPLS method with fully automated image measures performs as
well as the manually measured total hippocampal volume. The
results from the OPLS method using the fully automated MRI
measures and the results from the hippocampal volumes are in line
with our earlier results from the AddNeuroMed cohort and have
been discussed and compared to that of other groups previously
[6,9]. Comparing the results from the current study with
previously published work we found only one similar study which
compared a computerized technique (SVM) with neuroradiologist
evaluations [8]. In this prior study, two small cohorts of AD
patients and controls were evaluated (40 subjects in the first cohort
and 28 subjects in the second cohort). The SVM and visual
assessments gave prediction accuracies of 95% vs. 88.8%
respectively, for the first cohort, and 92.9% vs. 82.5% for the
second cohort. The SVM results were better than the OPLS
results that we report here for both cohorts, with the result from
the visual rating assessment results higher for their first cohort than
our study, but similar to our study for their second cohort. The
cohorts included in the study by Klo ¨ppel et al. were neuropatho-
logically confirmed and much smaller than the cohort investigated
in the present study, which is a likely explanation for the higher
prediction accuracy. Klo ¨ppel et al. also published another paper
[5] using pathologically confirmed data to distinguish between AD
and CTL using SVM. High prediction accuracies were again
obtained, up to 96% but the sample sizes were again smaller
(maximum 20 in each group). They also had a slightly larger
cohort (33 AD and 57 CTL) with probable mild AD subjects.
Using no feature selection, they obtained a prediction accuracy of
81.1% (sensitivity 60.6% and specificity 93.0%). Prediction
accuracies can sometimes be misleading, especially if one group
is much smaller than the other. In this present study using the
OPLS method with no feature selection on the automated
Table 3. Sensitivity/specificity and likelihood ratios for the different methods.
Sensitivity Specificity Accuracy LR+ LR2
Visual assessment 78.7 (68.1–86.4) 82.7 (73.1–89.4) 80.8 (73.9–86.2) 4.6 (2.8–7.4) 0.26 (0.16–0.40)
Fischl and Dale 77.3(66.7–85.3) 87.7 (78.7–93.2) 82.7 (75.6–87.8) 6.3 (3.5–11.3) 0.26 (0.17–0.40)
Manual outlining 93.3 (85.3–97.1) 85.2(75.9–91.3) 89.1 (83.2–93.1) 6.3(3.7–10.7) 0.08 (0.03–0.18)
Confidence intervals within parentheses, LR+=positive likelihood ratio and LR2=negative likelihood ratio.
doi:10.1371/journal.pone.0022506.t003
Table 4. MCI prediction.
Method Number AD-like CTL-like
Visual assessment converters 19 68% (13) 32% (6)
Fischl and Dale converters 19 74% (14) 26% (5)
Manual hippocampal volume converters 19 79% (15) 21% (4)
Visual assessment non-converters 82 32% (26) 68% (56)
Fischl and Dale non-converters 82 30% (24) 70% (58)
Manual hippocampal volume non-
converters
82 46% (38) 54% (44)
Results for fixed specificity Number
MCI-c
as AD
MCI-s
as CTL
Visual assessment 101 68% 68%
Fischl and Dale 101 79% 68%
Manual hippocampal volume 101 68% 68%
AD=Alzheimer’s disease, MCI=Mild Cognitive Impairment, CTL=healthy
control, MCI-c=MCI converters and MCI-s=MCI stable. To better compare the
performance of the three methods we also calculated the sensitivity (MCI-c
predicted as AD) at a fixed specificity (MCI-s predicted as CTL). We set the
specificity to that of the visual rating assessment and recalculated the sensitivity
and specificity of the other two methods used.
doi:10.1371/journal.pone.0022506.t004
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specificity 87.7%). As can be observed the accuracy of the latter
study by Kloppel et al is very similar to ours, but their sensitivity is
much lower. It is important that computerized analysis techniques
are validated in large cohorts, since it is easy for such methods to
fix onto features that may be different between small cohorts, but
are not generalizable to larger cohorts. Although neuropatholog-
ically confirmed data is preferred when evaluating these types of
automated models, it is very difficult to obtain large neuropatho-
logically confirmed datasets in practice. This is even more
pronounced when studying the prodromal stages of the disease.
MCI subjects are typically diagnosed approximately 10–15 years
before death, which makes longitudinal follow-up very difficult
and the acquisition of large neuropathologically confirmed
datasets with recent MRI an exceedingly difficult endeavor. At
the moment it is necessary to choose between small data sets which
are neuropathologically confirmed, but potentially not represen-
tative of the heterogeneity and complexity of Alzheimer’s disease,
and larger datasets such as ours, which are more representative
but not neuropathologically confirmed. A further advantage of our
study, compared to that of Klo ¨ppel et al. is that the images
acquired in our study are ADNI compatible, making our findings
generalizable to other large ADNI compatible cohorts.
The new research and diagnostic criterion have a strong focus
on the use of biomarkers including MRI, PET and CSF [2,3].
Although individual markers such as MRI can be powerful in AD,
we believe that combining different markers is an attractive
approach, particularly if considering differential diagnosis amongst
different forms of dementia. Neurodegeneration in AD is
estimated to start 20–30 years before the clinical diagnosis is
given [47] and so if diagnosis is to be made at the prodromal stage
of the disease then it may be necessary to combine several different
markers of disease. Previously we have shown that combining
regional MRI measures with magnetic resonance spectroscopy
results improves classification results, doubling the positive
likelihood ratio [7].
Predicting conversion from MCI at baseline to AD at one
year follow-up
At one year follow-up 19 of the 101 subjects with mild cognitive
impairment converted from MCI to AD while 82 remained stable.
One of the aims of this study was to compare how the three
methods performed in predicting conversion from MCI to AD.
The accuracy of predicting conversion varied from 68–79%. Total
manual hippocampal volume gave the best results, followed by the
OPLS approach including automated MRI measures and finally
the visual rating assessment. It is however difficult to confidently
state that one method is better than the other due to the small
numbers of subject converting. The three methods predict 15/19,
14/19 and 13/19 converters respectively as more AD like, which
is a small absolute difference that has a larger impact on the
percentage accuracy. The accuracy of the different models in
correctly predicting stable MCI subjects varied between from 54–
70%. Although the OPLS method gave the best results, subjects
diagnosed at baseline with MCI who are still classified as MCI at
one year follow up may subsequently convert to AD at a later stage
and thus assessing whether subjects will eventually convert to AD
may require longer follow up times. Further large studies with
longer follow up times are warranted to investigate this issue. To
make the comparison of the performance of the three methods
easier we calculated the sensitivity (MCI-c predicted as AD) at a
fixed specificity (MCI-s predicted as CTL). This yielded the best
sensitivity for the OPLS model with automated regional MRI
measures as input. This model predicted 79% of the MCI-c
subjects who converted to AD at one year follow-up as more AD-
like, compared to 68% of the other two methods. Although the
number of converters is relatively small, a likely explanation for
these results is that combining multiple regions across the brain
aids in the prediction of MCI conversion.
Conclusion
Visual rating assessment of the medial temporal lobe gave
similar prediction accuracy to computerized multivariate classifi-
cation and both accuracies are comparable to that of manual
hippocampal volume measurements. While manual hippocampal
volumes are a valuable research tool and have found utility in
clinical trials, they are not however practical for use in routine
clinical work. Our results demonstrate that computerized
multivariate classification is as good as expert radiological review
of MRI using a validated and widely used visual rating scale,
which suggests a potential future role for computerized methods as
a complement to clinical assessment. Improving classification
models by adding other biomarkers will hopefully increase the
predictive power of the models and improve our understanding of
the etiology of the disease. Two limitations of the current study are
however that the data is not neuropathologically confirmed and
that the follow-up of the MCI subjects was for one year.
In conclusion we believe that this study and previous work
[6,7,9] has shown that the OPLS model with automated MRI
measures as input has the potential to serve as a complement to
clinical assessment of AD, and to target appropriate populations
for clinical trials.
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